PT  - JOURNAL ARTICLE
AU  - Benchrifi, Younes
AU  - Nouri, Meriem
AU  - Elomri, Hajar
AU  - Benhessou, Mustapha
AU  - Ennachit, Simohamed
AU  - Elkarroumi, Mohammed
TI  - 674 HER2 positive breast cancer management: experience of the mohammed VI centre of onco-gynecology of the IBN ROCHD university hospital of Casablanca
AID  - 10.1136/ijgc-2024-ESGO.264
DP  - 2024 Mar 01
TA  - International Journal of Gynecologic Cancer
PG  - A140--A141
VI  - 34
IP  - Suppl 1
4099  - http://ijgc.bmj.com/content/34/Suppl_1/A140.2.short
4100  - http://ijgc.bmj.com/content/34/Suppl_1/A140.2.full
SO  - Int J Gynecol Cancer2024 Mar 01; 34
AB  - Introduction/Background Breast cancer is a heterogeneous disease. However, immunohistochemistry techniques have distinguished 3 types of breast cancer: those that express hormone receptors (most common 68%), others that express the HER2 growth factor receptor (21% of cases) and the triple negative molecular type.HER 2+ breast cancer is defined by the expression of HER2 receptors. Currently, the knowledge of its status vis-à-vis the HER2 receptor makes it possible to know if one can benefit from a targeted anti-HER2 treatment.Methodology This is a retrospective study of a series of 443 cases of positive HER2 breast cancer collected at the Mohammed VI oncology department at the University Hospital in Casablanca between January 2019 and December 2022.Results HER2+ breast cancer accounts for 21.1% of all breast cancers.On the epidemic-clinical level: There was a peak of frequency between 40 and 54 years, the most frequent reason for consultation was the nodule in 80% of cases.Anatomo-pathologically: Infiltrating ductal carcinoma is the most represented type in 97.56% of cases, with a predominance of the clinical stage T3. The histoprognostic grades SBR II and III each represent 32% and 59.3% of cases.Therapeutically: 17.5% of patients received conservative treatment, and 82.5% underwent radical surgery such as Patey. Adjuvant chemotherapy was administered in 68.84% of cases and 26.63% received neoadjuvant chemotherapy, 67% of our patients received hormonal therapy and 95% were put on targeted therapy. While for metastatic breast cancer: of 89 cases: 87 received systemic treatment of 1st line, 31 received treatment of 2nd line, 19 (3rd line) and 10 (4th line)Evolutionarily: 54.3% of women had good control while 22.72% developed local, locoregional and metastatic recurrences. The death rate was 12.3%.Conclusion Our research contributes significantly to the understanding of positive HER2 breast cancer in women, highlighting factors that influence management, treatment side effects and clinical outcomes.Disclosures Nothing to disclose.